Companies › Akeso
14 active drug programs in 196 registered trials: 112 Phase 2, 52 Phase 1, 31 Phase 3, 1 Phase 4; Oncology, Other, Infectious disease, Hematology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cadonilimab (AK104) Programmed cell death protein 1 inhibitor; Cytotoxic T-lymphocyte protein 4 inhibitor | PDCD1, CTLA4 | Phase 3 | Hepatocellular Carcinoma; Cervical Cancer; Gastric and Gastroesophageal Junction Adenocarcinoma; NSCLC (Non-small Cell Lung Cancer) … | Nov 2026 |
| pulocimab (AK109) PD-L2 monoclonal antibody | PD-L2 | Phase 3 | Gastric and Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma; Advanced Solid Tumor | Nov 2026 |
| Envafolimab (AK112) Programmed cell death 1 ligand 1 binding agent | CD274 | Phase 3 | Triple-Negative Breast Cancer (TNBC); Advanced Squamous Non Small Cell Lung Cancer; Advanced Non-small-cell Lung Cancer; Colorectal Adenocarcinoma … | Dec 2026 |
| Penpulimab (AK105) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Nasopharyngeal Carcinoma | Dec 2026 |
| AK117 anti-CD47 antibody | CD47 | Phase 3 | Head and Neck Squamous Cell Carcinoma; Higher-risk Myelodysplastic Syndromes; Metastatic Triple-negative Breast Cancer; Resectable Gastric or Gastroesophageal Junction Adenocarcinoma … | Dec 2026 |
| AK112 (Ivonescimab) Dual PD-1/TIGIT bispecific antibody | PDCD1, VEGFA | Phase 3 | Pancreatic Cancer; Non-Small Cell Lung Cancer; Platinum-sensitive Ovarian Cancer; Extensive-stage Small Cell Lung Cancer (ES-SCLC) | May 2027 |
| AK146D1 Anti-Trop2/Nectin4 bispecific antibody-drug conjugate | TROP2, NECTIN4 | Phase 2 | Advanced Non Small Cell Lung Cancer (NSCLC); Advanced Breast Cancer; Advanced Solid Tumors | May 2027 |
| AK130 Bispecific antibody | – | Phase 2 | Pancreatic Cancer; Biliary Tract Cancer; Hepatocellular Carcinoma | May 2027 |
| AK119 anti-CD73 monoclonal antibody | NT5E | Phase 1 | Colorectal Cancer; Solid Tumor, Adult | Dec 2026 |
| AK129 Bispecific antibody targeting LAG-3 and PD-1 | LAG3, PDCD1 | Phase 1 | Advanced Malignant Tumors(Stage IA-IB); Non-small Cell Lung Cancer Stage IIIB/IV; Classic Hodgkin Lymphoma | Dec 2026 |
| AK138D1 | – | Phase 1 | Solid Cancer; Non-Small Cell Lung Cancer | Feb 2028 |
| AK127 Bispecific antibody | – | Phase 1 | Advanced Malignant Tumors; Advanced Solid Tumors; Hepatocellular Carcinoma | Sep 2028 |
| AK131 anti-PD-1 and CD73 bispecific antibody | PDCD1, NT5E | Phase 1 | Solid Tumor | Dec 2028 |
| AK157D1 for injection | – | Phase 1 | Advanced Solid Tumors | Mar 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05319431 | Cadonilimab (AK104) | Phase 2 | Unresectable, Non-metastatic Hepatocellular Carcinoma | Oncology | Aug 2023 |
| NCT06532591 | Cadonilimab (AK104) | Phase 2 | NSCLC | Oncology | Apr 2025 |
| NCT05859750 | Cadonilimab (AK104) | Phase 2 | Pancreatic Cancer | Oncology | Jun 2025 |
| NCT05824481 | Cadonilimab (AK104) | Phase 2 | Endometrial Cancer | Oncology | Jul 2025 |
| NCT04980885 | AK117 | Phase 1 | Acute Myeloid Leukemia | Oncology | Sep 2025 |
| NCT04900350 | AK117 | Phase 1 | Myelodysplastic Syndrome | Hematology | Sep 2025 |
| NCT06371157 | Cadonilimab (AK104) | Phase 3 | Hepatocellular Carcinoma | Oncology | Oct 2025 |
| NCT04982237 | Cadonilimab (AK104) | Phase 3 | Cervical Cancer | Oncology | Dec 2025 |
| NCT05685550 | Envafolimab (AK112) | Phase 2 | Progression Free Survival(PFS) | Other | Dec 2025 |
| NCT06035224 | Cadonilimab (AK104) | Phase 2 | Clear Cell Renal Cell Carcinoma | Oncology | Jan 2026 |
| NCT06196203 | AK117 | Phase 2 | Higher-risk Myelodysplastic Syndromes | Hematology | Jan 2026 |
| NCT06809517 | Envafolimab (AK112) | Phase 1 | Leptomeningeal Metastasis | Oncology | Mar 2026 |
| NCT05868876 | Cadonilimab (AK104) | Phase 1 | Advanced Malignant Tumors | Oncology | Mar 2026 |
| NCT05868876 | AK127 | Phase 1 | Advanced Malignant Tumors | Oncology | Mar 2026 |
| NCT07340476 | Envafolimab (AK112) | Phase 1 | Healthy Male Subjects | Other | Apr 2026 |
| NCT05808608 | Cadonilimab (AK104) | Phase 1 | Renal Cell Carcinoma | Oncology | Apr 2026 |
| NCT05951608 | Envafolimab (AK112) | Phase 1 | Advanced Solid Tumors | Oncology | May 2026 |
| NCT06654011 | Cadonilimab (AK104) | Phase 2 | Cervical Adenocarcinoma | Oncology | May 2026 |
| NCT05951608 | AK127 | Phase 1 | Advanced Solid Tumors | Oncology | May 2026 |
| NCT05846867 | Envafolimab (AK112) | Phase 1 | Colorectal Cancer | Oncology | May 2026 |
| NCT05846867 | AK119 | Phase 1 | Colorectal Cancer | Oncology | May 2026 |
| NCT05932212 | Cadonilimab (AK104) | Phase 2 | Vulvar Cancer | Oncology | May 2026 |
| NCT05645276 | AK129 | Phase 1 | Advanced Malignant Tumors(Stage IA-IB) | Oncology | Jun 2026 |
| NCT06532539 | Cadonilimab (AK104) | Phase 2 | Endometrial Neoplasms | Oncology | Aug 2026 |
| NCT06762080 | Cadonilimab (AK104) | Phase 1 | Leptomeningeal Metastasis | Oncology | Oct 2026 |
| NCT06341335 | Cadonilimab (AK104) | Phase 3 | Gastric and Gastroesophageal Junction Adenocarcinoma | Oncology | Nov 2026 |
| NCT05644379 | Cadonilimab (AK104) | Phase 1 | Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy | Oncology | Nov 2026 |
| NCT06341335 | pulocimab (AK109) | Phase 3 | Gastric and Gastroesophageal Junction Adenocarcinoma | Oncology | Nov 2026 |
| NCT06438822 | Cadonilimab (AK104) | Phase 2 | Cholangiocarcinoma | Oncology | Nov 2026 |
| NCT07266493 | Envafolimab (AK112) | Phase 2 | Esophageal Squamous Cell Carcinoma | Oncology | Dec 2026 |
| NCT05926700 | Cadonilimab (AK104) | Phase 2 | Soft Tissue Sarcoma | Oncology | Dec 2026 |
| NCT06767527 | Envafolimab (AK112) | Phase 3 | Triple-Negative Breast Cancer (TNBC) | Oncology | Dec 2026 |
| NCT04736823 | Envafolimab (AK112) | Phase 2 | NSCLC | Oncology | Dec 2026 |
| NCT05689853 | Envafolimab (AK112) | Phase 1 | Solid Tumor, Adult | Oncology | Dec 2026 |
| NCT05689853 | AK119 | Phase 1 | Solid Tumor, Adult | Oncology | Dec 2026 |
| NCT04556253 | Cadonilimab (AK104) | Phase 2 | MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer | Oncology | Dec 2026 |
| NCT05687851 | Cadonilimab (AK104) | Phase 2 | Locally Advanced Cervical Cancer | Oncology | Dec 2026 |
| NCT06943820 | AK129 | Phase 1 | Non-small Cell Lung Cancer Stage IIIB/IV | Oncology | Dec 2026 |
| NCT04974398 | Penpulimab (AK105) | Phase 3 | Nasopharyngeal Carcinoma | Oncology | Dec 2026 |
| NCT05227664 | Envafolimab (AK112) | Phase 2 | Metastatic Triple-negative Breast Cancer | Oncology | Dec 2026 |
| NCT06646055 | Envafolimab (AK112) | Phase 1 | Metastatic Pancreatic Ductal Adenocarcinoma | Oncology | Dec 2026 |
| NCT07243626 | Envafolimab (AK112) | Phase 2 | Soft Tissue Sarcoma | Oncology | Dec 2026 |
| NCT06321081 | Envafolimab (AK112) | Phase 2 | RAS Mutation | Oncology | Dec 2026 |
| NCT05227664 | AK117 | Phase 2 | Metastatic Triple-negative Breast Cancer | Oncology | Dec 2026 |
| NCT06646055 | Cadonilimab (AK104) | Phase 1 | Metastatic Pancreatic Ductal Adenocarcinoma | Oncology | Dec 2026 |
| NCT06467500 | Cadonilimab (AK104) | Phase 2 | Non-small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT05840016 | Envafolimab (AK112) | Phase 3 | Advanced Squamous Non Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT05499390 | Envafolimab (AK112) | Phase 3 | Advanced Non-small-cell Lung Cancer | Oncology | Dec 2026 |
| NCT05229497 | Envafolimab (AK112) | Phase 1 | Advanced Malignant Tumors | Oncology | Dec 2026 |
| NCT07852091 | Envafolimab (AK112) | Phase 2 | Chronic Hepatitis B | Infectious disease | Dec 2026 |
| NCT05959356 | Envafolimab (AK112) | Phase 2 | Metastatic Colorectal Cancer | Oncology | Dec 2026 |
| NCT05959356 | Envafolimab (AK112) | Phase 2 | Metastatic Colorectal Cancer | Oncology | Dec 2026 |
| NCT05397769 | Envafolimab (AK112) | Phase 2 | Locally Advanced Nasopharyngeal Carcinoma | Oncology | Dec 2026 |
| NCT05229497 | AK117 | Phase 1 | Advanced Malignant Tumors | Oncology | Dec 2026 |
| NCT06218810 | Cadonilimab (AK104) | Phase 2 | Metastatic Colorectal Cancer | Oncology | Dec 2026 |
| NCT06587425 | Cadonilimab (AK104) | Phase 2 | Gastric or Gastroesophageal Junction Adenocarcinoma | Oncology | Dec 2026 |
| NCT06769971 | Cadonilimab (AK104) | Phase 2 | Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT07104149 | Cadonilimab (AK104) | Phase 2 | Female, Age ≥ 18 Years Old | Oncology | Dec 2026 |
| NCT06728631 | Cadonilimab (AK104) | Phase 2 | Oral Cavity Cancer | Oncology | Dec 2026 |
| NCT06477523 | Cadonilimab (AK104) | Phase 1 | SCLC, Extensive Stage | Oncology | Dec 2026 |
The 60 nearest readouts of 196 trials; the rest in the app.
Shanghai Henlius Biotech Shenyang Sunshine Pharmaceutical Sichuan Baili Pharmaceutical Mabwell (Shanghai) Bioscience Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.